Anika Therapeutics is a global joint preservation company. Co. has divided its product portfolio into three product families: Joint Pain Management, which include Monovisc and Orthovis, Cingal and Hyvisc; Joint Preservation and Restoration, which include bone preserving joint technologies; soft tissue repair and regenerative solutions; and Other, which consists of Hyalobarrier, an anti-adhesion barrier indicated for use after abdomino-pelvic surgeries, and Hyalomatrix, which is used for the treatment of complex wounds such as burns and ulcers, products used in connection with the treatment of ears, nose and throat disorders, and ophthalmic products. The ANIK stock yearly return is shown above.
The yearly return on the ANIK stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2016 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ANIK annual return calculation with any dividends reinvested as applicable (on ex-dates).
|